
|Articles|April 17, 2020
Quiz: Evolving Treatment Options in BRAF V600E Mutant Metastatic Colorectal Cancer
Author(s)Hannah Slater
In our gastrointestinal cancer quiz, you’ll get a chance to test your knowledge on the BRAF V600E mutation in patients with colorectal cancer.
Advertisement
In our gastrointestinal cancer quiz, you’ll get a chance to test your knowledge on the BRAF V600E mutation in patients with colorectal cancer. Here’s your first question:
1. What combination treatment was studied in the BEACON CRC study of patients with BRAF V600E mutated metastatic colorectal cancer?
A. Encorafenib (Braftovi), cetuximab (Erbitux), and binimetinib (Mektovi)
B. Vemurafenib (Zelboraf), dabrafenib, and trametinib
C. Dabrafenib, cetuximab, and encorafenib
D. Vemurafenib, trametinib, and binimetinib
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications
2
Where Does LAG-3/PD-1 Inhibition Fit In PD-1–Refractory Hodgkin Lymphoma?
3
VS-7375 Exhibits Activity in KRAS G12D–Mutated Solid Tumors
4
GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations
5



















































































